-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma trustee buys 50,000 shares for 2022 RSU scheme, pays HK$1.91 million

PUBT·05/28/2026 13:57:00
Listen to the news
Ascentage Pharma trustee buys 50,000 shares for 2022 RSU scheme, pays HK$1.91 million
  • Ascentage Pharma set additional funding for its 2022 RSU Scheme via an on-market trustee purchase of 50,000 shares on May 28, 2026.
  • Total consideration was HK$ 1,909,800, implying an average price of HK$ 38.2 per share.
  • The purchase equals about 0.01% of issued share capital.
  • Trustee-held shares acquired for the 2022 RSU Scheme rose to 2,315,000 shares immediately following the transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260528-12175641), on May 28, 2026, and is solely responsible for the information contained therein.